


# REAL-WORLD USE, PERSISTENCE, AND ADHERENCE TO BIOLOGIC THERAPIES IN HIDRADENITIS SUPPURATIVA

R. SIMAL LÓPEZ<sup>1</sup>, A. PINILLA RELLO<sup>1</sup>, M. PÉREZ HUERGA<sup>1</sup>, E. CHILET RODRIGO<sup>1</sup>, S. DE LA FUENTE MEIRA<sup>2</sup>, E. FERNÁNDEZ ALONSO<sup>1</sup>, M. GIMENO GRACIA<sup>1</sup>, I. NAVARRO PARDO<sup>1</sup>, M.Á. ALLENDE BANDRÉS<sup>1</sup>, J.R. LOZANO ORTIZ<sup>1</sup>, M. MERCHANTE ANDREU<sup>1</sup>

<sup>1</sup>HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA, PHARMACY, ZARAGOZA, SPAIN.

<sup>2</sup>HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA, DERMATOLOGY, ZARAGOZA, SPAIN.

## BACKGROUND AND IMPORTANCE



Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disorder that significantly impacts both physical and psychological well-being.




Adalimumab was the first biologic approved for HS, with newer agents such as secukinumab and bimekizumab targeting the IL-17 pathway.



Adherence and persistence to treatment are crucial for ensuring therapeutic efficacy and optimizing health outcomes in hospital pharmacy settings

## AIM AND OBJECTIVE

To describe the profile of patients with HS treated with adalimumab, secukinumab, or bimekizumab, and to assess the persistence of these biologic therapies in a tertiary care hospital.



## MATERIAL AND METHODS



- This is a retrospective, observational, single-center study.
- Patients treated with biologics (adalimumab, secukinumab, or bimekizumab) for HS from August 5, 2015, to August 29, 2025.


## DATA COLLECTED




- Age
  - Sex
  - Adherence
  - Treatment initiation
  - Reason for treatment change
  - Treatment duration
- Defined as a possession rate  $\geq 90\%$  based on dispensing records

## RESULTS


119 patients with a mean age of  $44 \pm 12.0$  years were included. 74 (62.2%) were male.




All changes of treatment were due to ineffectiveness or lack of response



ACTUAL REGIMEN	ADALIMUMAB (n=75)	SECUKINUMAB (n=39)	BIMEKIZUMAB (n=5)
Weekly	96,0%	7,7%	-
Biweekly	4%	38,5%	3
Monthly	-	53,8%	1
Bimonthly	-	-	1



TREATMENT	PERSISTENCE (DAYS)	IC (95%)
ADALIMUMAB	441	299.6-582.4
SECUKINUMAB	245	171.3-318.7
BIMEKIZUMAB	190	13.1-458.4



## CONCLUSION AND RELEVANCE



- Adalimumab remains the most widely used and persistent treatment, while secukinumab stands out for its high adherence.
- These findings highlight the importance of hospital pharmacy monitoring to optimize patient outcomes and inform clinical decision-making in biologic therapy selection.

